We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Raises Target Price to $10
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $11
Diamedica Therapeutics (DMAC) Gets a Buy From Lake Street
Diamedica Therapeutics Is Maintained at Buy by HC Wainwright & Co.
DiaMedica Therapeutics Analyst Ratings
Buy Rating for Diamedica Therapeutics Driven by Promising DM199 Developments and Upcoming Trial Results
Express News | DiaMedica Therapeutics Inc. : H.c. Wainwright Raises Target Price to $10 From $7
DiaMedica Therapeutics Shares Are Trading Lower Following a FY24 EPS Miss.
Express News | DiaMedica Therapeutics Shares Are Trading Lower Following a FY24 EPS Miss
DiaMedica Therapeutics Reports 2024 Financial Results and Strategic Advancements
DIAMEDICA THERAPEUTICS Earnings Results: $DMAC Reports Quarterly Earnings
Express News | DiaMedica Therapeutics: Preeclampsia Phase 2 Trial Preliminary Topline Safety, Efficacy Data From Part 1a of Study Expected in Q2 2025
DiaMedica Therapeutics | 10-K: FY2024 Annual Report
Diamedica Therapeutics Sees Funding Sufficent Into 3Q26 >DMAC
Diamedica Therapeutics 2024 Loss/Shr 60c >DMAC
Express News | DiaMedica Therapeutics Expects Cash Runway Into Q3 2026
Express News | DiaMedica Therapeutics FY 2024 GAAP EPS $(0.60) Misses $(0.59) Estimate
Press Release: DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results